Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your ...

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene ...

In a new study just published in the European Heart Journal, researchers from Herlev and Gentofte Hospital quantify for the first time how life expectancy and cardiovascular disease in people ...

Explore latest progress in siRNA chemistry to increase activity, stability, specificity & potential off target effects to improve cellular targeting with insights from Silence Therapeutics & Aro ...

European equities traded in the US as American depositary receipts were trending sharply higher late Wednesday morning, rising 1.36% to 1,375.76 on the S&P Europe Select ADR Index. From continental ...